Evidence-Based Minireview: Does achieving MRD negativity after initial therapy improve prognosis for high-risk myeloma patients?

Evidence-Based Minireview: Does achieving MRD negativity after initial therapy improve prognosis for high-risk myeloma patients? Hematology Am Soc Hematol Educ Program. 2019 Dec 06;2019(1):142-147 Authors: Sidana S, Manasanch E Abstract You are evaluating a 47-year-old man with revised international staging system stage III myeloma who recently underwent an autologous stem cell transplant after receiving 6 cycles of carfilzomib, lenalidomide, and dexamethasone for newly diagnosed disease. Fluorescence in situ hybridization testing at initial presentation also revealed t(4;14). On day 100 evaluation after transplant, he has achieved a stringent complete response. Two-tube, 8-color advanced flow cytometry with a sensitivity of 10-5 shows no minimal residual disease. Whole-body positron emission tomography/computed tomography scan shows resolution of all fluorodeoxyglucose avid uptake seen at diagnosis. The patient asks you how these test results impact his prognosis and whether this overcomes his baseline high risk from t(4;14)? PMID: 31808853 [PubMed - in process]
Source: Hematology ASH Education Program - Category: Hematology Tags: Hematology Am Soc Hematol Educ Program Source Type: research

Related Links:

mopoulos MA Abstract Here, we are reporting the outcome of 226 myeloma patients presenting with extramedullary plasmacytoma or paraosseous involvement in a retrospective study conducted in 19 centers from 11 countries. Extramedullary disease was detected at diagnosis or relapse between January 2010 and November 2017. Extramedullary plasmacytoma and paraosseous involvement were observed in 130 patients at diagnosis (92/38) and in 96 at relapse (84/12). The median time from multiple myeloma diagnosis to the development of extramedullary disease was 25.1 months (range 3.1-106.3 months) in the relapse group (median fo...
Source: Haematologica - Category: Hematology Authors: Tags: Haematologica Source Type: research
Conclusions Several model systems are now available to characterize the MSC-tumour interplay in the TME. These offer early promise in establishing robust preclinical platforms for the identification of crucial molecular pathways and for the assessment of clinical efficacy of novel drugs to inhibit cancer development and progression. However, selection of the right model for a given study should be shaped on the purpose, and should also consider fixed biological, biochemical, and biophysical parameters according to the specific tumour type. Finally, in order to get reliable and useful results to be translated to the clinic...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
Introduction: Over the past years, possible use of PET/CT scan for diagnosis of multiple myeloma has been intensively studied; there is evidence that the use of 11C-methionine instead of 18F-fludeoxyglucose (18F-FDG) in multiple myeloma patients promotes the decrease in false negative PET/CT scan results. Comparative evaluation of the efficacy of detection of residual tumor lesions in MM patients following auto-HSCT using different radiopharmaceuticals for PET/CT scans is an important task.Goal of the study: To compare the results of tumor imaging using 18F-FDG and 11C-methionine PET/CT scan in MM patients following auto-H...
Source: Blood - Category: Hematology Authors: Tags: 731. Clinical Autologous Transplantation: Results: Poster II Source Type: research
Conclusions: CyBorD-DARA is a highly active, well tolerated induction therapy for NDMM patients undergoing ASCT. These data support the further development of this combination as a convenient, cost effective alternative to PI-IMiD-DARA based combinations.DisclosuresQuinn: Janssen: Honoraria. O'Dwyer: Janssen: Membership on an entity's Board of Directors or advisory committees, Research Funding; Celgene: Research Funding; Glycomimetics: Research Funding; Onkimmune: Equity Ownership, Membership on an entity's Board of Directors or advisory committees, Research Funding; Abbvie: Membership on an entity's Board of Directors or ...
Source: Blood - Category: Hematology Authors: Tags: 653. Myeloma: Therapy, excluding Transplantation: Poster II Source Type: research
IntroductionCompliance with Multiple Myeloma (MM) recommendations regarding diagnosis and treatment is highly variable worldwide, outside clinical trials. This survey among hematologists from Latin America (LA) aims to describe real access to diagnostic and prognostic analyses and first line treatment for newly diagnosed MM (NDMM).ObjectivesTo describe the access to diagnostic and prognostic tests and first line treatment options for MM in LA.To compare public versus private access to tests and therapies.MethodsThis is a multicenter cross-sectional study. A 16-question survey focusing on demographic characteristics of phys...
Source: Blood - Category: Hematology Authors: Tags: 902. Health Services Research-Malignant Diseases: Poster I Source Type: research
BACKGROUND:Multiple Myeloma (MM) is a heterogenous disease with variable outcomes based on both disease biology and burden. The revised international staging system (R-ISS) can distinguish 5-year overall survival (OS) however, it does not incorporate novel imaging that provide more accurate disease burden assessment (e.g., PET-CT). Previous studies (Usmani SZ et al Blood 2013) showed that the presence of more than 3 focal lesions (FL)s detected on PET-CT scan at baseline in newly diagnosed MM patients, or the persistence of any FL post induction therapy or post- autologous stem cell transplantation (ASCT), were associated ...
Source: Blood - Category: Hematology Authors: Tags: 651. Myeloma: Biology and Pathophysiology, excluding Therapy Source Type: research
Conclusions: 18F-FDG PET / CT helps to make FL patient’s treatment decisions by suggesting histological large cell transformation, clarifying clinical staging and finding treatment indications.
Source: Journal of Nuclear Medicine - Category: Nuclear Medicine Authors: Tags: Leukemia/Lymphoma/Myeloma Poster Session Source Type: research
Conclusion: In patients with relapsing or refractory DLBCL treated with R-DHAC salvage therapy followed by ASCT, pre-transplant 18-FDG PET/CT SUVmax and whole-body TLG remains the strongest predictive factors of PFS and OS. While a Deauville score of 5 also carries a dismal prognosis, a Deauville score of 4 does not appear to preclude a successful ASCT.
Source: Journal of Nuclear Medicine - Category: Nuclear Medicine Authors: Tags: Leukemia/Lymphoma/Myeloma Poster Session Source Type: research
A 70-year-old German man presented with a complex hepatic mass in liver segments V, VIII, and IVb (Figure 1), but without abdominal symptoms. Due to known multiple myeloma, the patient had undergone an autologous stem cell transplantation 11 years earlier, followed by treatment with the immunomodulator lenalidomide, leading to stable remission. A computed tomography (CT) scan obtained 4 years earlier had shown a much smaller lesion (3cm in size) in the same location, which had been interpreted as a partially thrombosed haemangioma.
Source: International Journal of Infectious Diseases - Category: Infectious Diseases Authors: Tags: Medical Imagery Source Type: research
azarbachi A Abstract Disease relapse remains the first cause of mortality of hematological malignancies after allogeneic hematopoietic stem cell transplantation (allo-HCT). The risk of recurrence is elevated in patients with high-risk cytogenetic or molecular abnormalities, as well as when allo-HCT is performed in patients with refractory disease or with persistent molecular or radiological (PET-CT scan) residual disease. Within the frame of the 7th annual workshops of the francophone society for bone marrow transplantation and cellular therapy, the working group reviewed the literature in order to elaborate ...
Source: Bulletin du Cancer - Category: Cancer & Oncology Authors: Tags: Bull Cancer Source Type: research
More News: CT Scan | Dexamethasone | Education | Hematology | Myeloma | PET Scan | Revlimid | Stem Cell Therapy | Stem Cells | Transplants | Universities & Medical Training